BidaskClub Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold

BidaskClub downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research note released on Saturday, BidAskClub reports.

A number of other analysts have also commented on ALNY. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an overweight rating on the stock in a report on Wednesday, August 7th. Barclays reissued a buy rating and issued a $125.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th. UBS Group upped their price objective on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a neutral rating in a research note on Wednesday, September 4th. ValuEngine raised Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Finally, Goldman Sachs Group reaffirmed a neutral rating and set a $80.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 23rd. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of Buy and an average target price of $116.13.

NASDAQ:ALNY opened at $84.27 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28. The firm has a market cap of $8.88 billion, a price-to-earnings ratio of -11.13 and a beta of 2.35. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $103.50. The firm has a 50-day moving average price of $79.52 and a two-hundred day moving average price of $78.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.06) by $0.04. The firm had revenue of $38.20 million for the quarter, compared to analysts’ expectations of $42.24 million. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.61) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -8.21 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its position in Alnylam Pharmaceuticals by 41.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 225,148 shares of the biopharmaceutical company’s stock worth $16,412,000 after buying an additional 66,253 shares during the last quarter. Geode Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 915,533 shares of the biopharmaceutical company’s stock valued at $66,708,000 after acquiring an additional 34,770 shares during the period. Quadrant Capital Group LLC lifted its holdings in Alnylam Pharmaceuticals by 543.2% during the first quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 440 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Alnylam Pharmaceuticals by 3.4% during the first quarter. Janus Henderson Group PLC now owns 25,243 shares of the biopharmaceutical company’s stock valued at $2,360,000 after purchasing an additional 841 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Alnylam Pharmaceuticals by 2.5% during the first quarter. Rhumbline Advisers now owns 92,891 shares of the biopharmaceutical company’s stock valued at $8,681,000 after purchasing an additional 2,295 shares during the last quarter. Institutional investors and hedge funds own 94.26% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Recommended Story: Initial Coin Offering (ICO)

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit